Massive Bio shared on Linkedin:
“Massive Bio has made its inaugural strategic investment in another AI company.
Rivvi AI, an agentic AI infrastructure company for healthcare and life sciences.
The investment connects our prospectively validated oncology intelligence with Rivvi’s agentic AI layer, moving patients from identification to informed action, with clinicians and navigators guiding every step.
Announced today at Ai4 – Artificial Intelligence Conferences 2026 in Las Vegas.
Read the Full release.”
Arturo LoAIza-Bonilla, Systemwide Chief of Hematology and Oncology at St. Luke’s University Health Network, and Co-Founder and Chief Medical AI Officer (CMAIO) of Massive Bio, shared a post by Massive Bio, adding:
“The transaction establishes a repeatable model for Massive Bio to evaluate and selectively invest in AI companies that strengthen the patient journey.
Massive Bio brings clinical evidence standards, oncology domain expertise, pharmaceutical and health-system relationships, and experience deploying across 17 countries.
Rivvi contributes specialized infrastructure for personalized healthcare conversations, workflow governance, and rapid operational scale.”
Other articles of Massive Bio on OncoDaily.